Advertisement

COPD pp 219-242 | Cite as

Pharmacologic Management

  • Seong Yong LimEmail author
Chapter
  • 1.1k Downloads

Abstract

ICS are the cornerstone of anti-inflammatory agents in asthma, and are recommended as monotherapy or combination with long-acting beta2-agonists (LABA) or leukotriene receptor antagonists. In contrast to the crucial role in asthma, evidence that ICS therapy is beneficial to patients with COPD is limited. ICS provide little benefit in COPD patients and are generally reserved for patients with severe COPD with frequent exacerbations or asthma-COPD overlap syndrome.

References

  1. 1.
    Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117:522–43.PubMedGoogle Scholar
  2. 2.
    Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27:413–26.PubMedGoogle Scholar
  3. 3.
    Adcock IM, Barnes PJ. Molecular mechanisms of corticosteroid resistance. Chest. 2008;134:394–401.PubMedGoogle Scholar
  4. 4.
    Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol. 2000;20:6891–903.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Barnes PJ. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin Immunol. 2007;119:1055–62. quiz 63-4.PubMedGoogle Scholar
  6. 6.
    Jiang Z, Zhu L. Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2016;37:1–8.PubMedGoogle Scholar
  7. 7.
    Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352:1967–76.PubMedGoogle Scholar
  8. 8.
    Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12:543–59.PubMedGoogle Scholar
  9. 9.
    Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med. 2006;203:7–13.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Vestbo J, Søorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353:1819–23.PubMedGoogle Scholar
  11. 11.
    Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340:1948–53.PubMedGoogle Scholar
  12. 12.
    Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297–303.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343:1902–9.Google Scholar
  14. 14.
    Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58:937–41.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Highland KB, Strange C, Heffner JE. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003;138:969–73.PubMedGoogle Scholar
  16. 16.
    Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002991.Google Scholar
  17. 17.
    Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332–8.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151:517–27.PubMedGoogle Scholar
  20. 20.
    Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J. 2009;34:13–6.PubMedGoogle Scholar
  21. 21.
    Telenga ED, Kerstjens HA, Postma DS, Ten Hacken NH, van den Berge M. Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opin Pharmacother. 2010;11:405–21.PubMedGoogle Scholar
  22. 22.
    Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–31. discussion 3-7.PubMedGoogle Scholar
  23. 23.
    Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398–404.PubMedGoogle Scholar
  24. 24.
    Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.Google Scholar
  25. 25.
    Zervas E, Samitas K, Gaga M, Beghe B, Fabbri LM. Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets. 2013;14:192–224.PubMedGoogle Scholar
  26. 26.
    Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59–65.PubMedGoogle Scholar
  27. 27.
    Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:842–6.PubMedGoogle Scholar
  28. 28.
    Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: a systematic review and metaregression of randomized controlled trials. Chest. 2010;137:318–25.PubMedGoogle Scholar
  29. 29.
    Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax. 2005;60:992–7.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest. 2006;130:640–6.PubMedGoogle Scholar
  31. 31.
    Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149:380–90.PubMedGoogle Scholar
  32. 32.
    Lofdahl CG, Postma DS, Pride NB, Boe J, Thoren A. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur Respir J. 2007;29:1115–9.PubMedGoogle Scholar
  33. 33.
    Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:2407–16.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Suissa S. Observational studies of inhaled corticosteroids in chronic obstructive pulmonary disease: misconstrued immortal time bias. Am J Respir Crit Care Med. 2006;173:464. author reply -5.PubMedGoogle Scholar
  35. 35.
    Loke YK, Kwok CS, Singh S. Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD. Eur Respir J. 2010;35:1003–21.PubMedGoogle Scholar
  36. 36.
    Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–65.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Gruffydd-Jones K, Loveridge C. The 2010 NICE COPD guidelines: how do they compare with the GOLD guidelines? Prim Care Respir J. 2011;20:199–204.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002;19:182–91.PubMedGoogle Scholar
  39. 39.
    Newton R, Leigh R, Giembycz MA. Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther. 2010;125:286–327.PubMedGoogle Scholar
  40. 40.
    Barnes PJ. Inhaled corticosteroids. Pharmaceuticals (Basel). 2010;3:514–40.Google Scholar
  41. 41.
    Pelaia G, Muzzio CC, Vatrella A, Maselli R, Magnoni MS, Rizzi A. Pharmacological basis and scientific rationale underlying the targeted use of inhaled corticosteroid/long-acting beta2-adrenergic agonist combinations in chronic obstructive pulmonary disease treatment. Expert Opin Pharmacother. 2015;16:2009–21.PubMedGoogle Scholar
  42. 42.
    Sin DD, Man SF. Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol. 2006;533:28–35.PubMedGoogle Scholar
  43. 43.
    Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005;172:704–12.PubMedGoogle Scholar
  44. 44.
    Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Phys. 1995;268:L41–6.Google Scholar
  45. 45.
    Mak JC, Nishikawa M, Shirasaki H, Miyayasu K, Barnes PJ. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest. 1995;96:99–106.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:1207–14.PubMedGoogle Scholar
  47. 47.
    Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:1084–91.PubMedGoogle Scholar
  48. 48.
    Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–56.PubMedGoogle Scholar
  49. 49.
    Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–9.PubMedGoogle Scholar
  50. 50.
    Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525–37.PubMedGoogle Scholar
  51. 51.
    Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011;5:44–9.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136:1029–38.PubMedGoogle Scholar
  53. 53.
    Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844.Google Scholar
  54. 54.
    Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med. 2014;8:357–79.PubMedGoogle Scholar
  55. 55.
    Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mug; 100/25 mug) on lung function in COPD. Respir Med. 2013;107:560–9.PubMedGoogle Scholar
  56. 56.
    Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mug) improves lung function in COPD: a randomised trial. Respir Med. 2013;107:550–9.PubMedGoogle Scholar
  57. 57.
    Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J. 2014;43:763–72.PubMedGoogle Scholar
  58. 58.
    Calverley PM, Kuna P, Monso E, et al. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010;104:1858–68.PubMedGoogle Scholar
  59. 59.
    Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis. 2012;7:73–86.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51–60.PubMedGoogle Scholar
  61. 61.
    Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–26.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109:870–81.PubMedGoogle Scholar
  63. 63.
    Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest. 2003;124:834–43.PubMedGoogle Scholar
  64. 64.
    Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2013;22:92–100.PubMedGoogle Scholar
  65. 65.
    Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81.PubMedGoogle Scholar
  66. 66.
    Blais L, Forget A, Ramachandran S. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin Ther. 2010;32:1320–8.PubMedGoogle Scholar
  67. 67.
    Larsson K, Janson C, Lisspers K, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273:584–94.PubMedGoogle Scholar
  68. 68.
    Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741–50.PubMedGoogle Scholar
  69. 69.
    Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26.PubMedGoogle Scholar
  70. 70.
    Tashkin DP. Preventing and managing exacerbations in COPD—critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis. 2010;5:41–53.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364:1093–103.PubMedGoogle Scholar
  72. 72.
    Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210–23.PubMedGoogle Scholar
  73. 73.
    De Soyza A, Calverley PM. Large trials, new knowledge: the changing face of COPD management. Eur Respir J. 2015;45:1692–703.PubMedGoogle Scholar
  74. 74.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–42.PubMedGoogle Scholar
  75. 75.
    Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–62.PubMedGoogle Scholar
  76. 76.
    Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192:523–5.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374:2222–34.PubMedGoogle Scholar
  78. 78.
    Miravitlles M, D'Urzo A, Singh D, Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir Res. 2016;17:112.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;11:CD003794.Google Scholar
  80. 80.
    Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8:CD006826.Google Scholar
  81. 81.
    Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9:CD006829.Google Scholar
  82. 82.
    La Vecchia C, Fabbri LM. Prevention of death in COPD. N Engl J Med. 2007;356:2211–2. author reply 3-4.PubMedGoogle Scholar
  83. 83.
    Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31:927–33.PubMedGoogle Scholar
  84. 84.
    Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007:CD006829.Google Scholar
  85. 85.
    Dong YH, Lin HH, Shau WY, Wu YC, Chang CH, Lai MS. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax. 2013;68:48–56.PubMedGoogle Scholar
  86. 86.
    Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41:1017–22.PubMedGoogle Scholar
  87. 87.
    Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–26.PubMedGoogle Scholar
  88. 88.
    Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;5:CD007891.Google Scholar
  89. 89.
    Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2016. www.goldcopd.org. Accessed 21 Jan 2016.
  90. 90.
    Montuschi P, Malerba M, Macis G, Mores N, Santini G. Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discov Today. 2016;21:1820–7.PubMedGoogle Scholar
  91. 91.
    James GD, Donaldson GC, Wedzicha JA, Nazareth I. Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study. NPJ Prim Care Respir Med. 2014;24:14015.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–55.PubMedGoogle Scholar
  93. 93.
    Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med. 2012;106:382–9.PubMedGoogle Scholar
  94. 94.
    Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med. 2014;25:491–5.PubMedGoogle Scholar
  95. 95.
    Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–94.PubMedPubMedCentralGoogle Scholar
  96. 96.
    Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388:963–73.PubMedGoogle Scholar
  97. 97.
    Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest. 2004;126:213–9.PubMedGoogle Scholar
  98. 98.
    Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician’s perception. Chest. 2006;130:41S–53S.PubMedGoogle Scholar
  99. 99.
    Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:171–5.PubMedGoogle Scholar
  100. 100.
    Babu KS, Kastelik JA, Morjaria JB. Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective. Br J Clin Pharmacol. 2014;78:282–300.PubMedPubMedCentralGoogle Scholar
  101. 101.
    Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015;12:27–34.PubMedGoogle Scholar
  102. 102.
    Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–36.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med. 2014;2:919–32.PubMedGoogle Scholar
  105. 105.
    Kunz LI, Postma DS, Klooster K, et al. Relapse in FEV1 decline after steroid withdrawal in COPD. Chest. 2015;148:389–96.PubMedGoogle Scholar
  106. 106.
    Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–8.PubMedGoogle Scholar
  107. 107.
    Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast—a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010;23:235–56.PubMedGoogle Scholar
  108. 108.
    Sanz MJ, Cortijo J, Morcillo EJ. PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression. Pharmacol Ther. 2005;106:269–97.PubMedGoogle Scholar
  109. 109.
    Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53–67.PubMedPubMedCentralGoogle Scholar
  110. 110.
    Beghe B, Rabe KF, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med. 2013;188:271–8.PubMedGoogle Scholar
  111. 111.
    Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–94.Google Scholar
  113. 113.
    Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting beta2-agonists for COPD: influence of exacerbation history. Eur Respir J. 2011;38:553–60.PubMedGoogle Scholar
  114. 114.
    Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013;143:1302–11.PubMedGoogle Scholar
  115. 115.
    Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–66.PubMedGoogle Scholar
  116. 116.
    Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90.PubMedPubMedCentralGoogle Scholar
  117. 117.
    Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther. 2012;91:134–42.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Division of Pulmonary and Critical Care Medicine, Department of MedicineKangbuk Samsung Hospital, Sungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations